がんワクチン市場予測：製品タイプ、製剤、投与経路、開発フェーズ、適応症、エンドユーザー別：2025～2030年

がんワクチンの市場は、2024年に71億1,000万米ドルと評価され、2025年にはCAGR 9.60%で77億8,000万米ドルに成長し、2030年には123億3,000万米ドルに達すると予測されています。

がんワクチン市場は、先端治療ソリューションの中で最も有望なセグメントの一つとして浮上しており、科学的な進化と、がんの世界の負担に対処する緊急性の高まりを反映しています。過去数十年にわたり、免疫学とバイオテクノロジーにおける飛躍的な進歩は、悪性腫瘍と闘う身体の能力に関する我々の理解を一変させました。この進歩は、免疫系を利用してがん細胞を同定し、標的とする発見に支えられており、予防法と治療法の両方に道を開いてきました。

最近の動向は、これらのワクチンの背景にある科学的根拠を拡大しただけでなく、新規の臨床応用や変革的な規制経路にもつながっています。画期的な研究、患者中心の治療、戦略的提携の融合は、市場力学を加速させ、同時に世界規模での競合情勢を再構築しています。この進化する市場の各側面を掘り下げていく中で、現代の腫瘍学において重要な柱として急速に台頭している学際的な要因を認識することが不可欠です。

本概要は、現在の動向、市場セグメンテーション洞察、世界の地域的影響、主要企業の躍進、戦略的提言を明確にし、意思決定者や産業専門家が複雑化する市場をナビゲートするのに役立つ包括的な概要を記載しています。このレンズを通して、利害関係者は技術革新サイクル、規制環境、技術進歩とがん治療パラダイムの間のダイナミックな相互作用をよりよく理解することができます。

ダイナミックながんワクチンセクタにおける変革的変化

近年、がんワクチンの情勢は、科学的ブレークスルー、製造技術の向上、規制当局の支援強化が相まって、激震的な変化を遂げています。この進化は、伝統的免疫学的原理に根ざしつつも、その範囲と高度さを飛躍的に拡大した革新的な治療法別支えられています。いくつかの革新的な動向が現れています。

第一に、個別化医療がますます重視されるようになり、個々の腫瘍抗原に基づいてオーダーメイドのワクチンが開発されています。この戦略は治療の精度を高めるだけでなく、オフ対象効果を最小化し、患者の予後改善につながります。最先端のゲノムとプロテオミクスプロファイリングの統合は、新規対象の同定に役立っており、それによってワクチン設計が洗練されています。

これと並行して、このセグメントでは製剤技術の進歩も著しいです。核酸ベースのワクチンのような最先端のプラットフォームは、迅速な設計とスケーラブルな生産に新たな道を開き、新規治療法の市場投入競争におけるフロントランナーとして位置づけられています。細胞ベースや合成ワクチン製剤を含む改良法も、安全性プロファイル、有効性、送達メカニズムを改善するために改良されています。

もう一つの大きな変化は、製薬会社、学術機関、規制当局の戦略的協力体制に見られるもので、臨床検査における従来の障害を大幅に軽減し、商業化への道を加速させています。さらに、ワクチン研究における人工知能とビッグデータ分析の統合は、研究開発プロセスを合理化するだけでなく、疾病メカニズムに対するより深い洞察をも明らかにしています。

最後に、患者の期待の変化とがん研究に対する公的投資の増加は、新興企業にも既存企業にも継続的な技術革新を促す原動力となっています。これらの要因は総体として活気ある市場状況に寄与しており、主要産業関係者はこうした破壊的な変化に対応して戦略的枠組みを再評価し、再編成する必要に迫られています。

詳細な市場分析のための包括的なセグメンテーション洞察

市場セグメンテーションを正確に理解することは、がんワクチン市場を定義する多様な層を理解する上で不可欠です。市場は主に製品タイプに基づいてセグメント化され、予防用がんワクチンと治療用がんワクチンの詳細な分析が行われています。この区分により、予防的介入であれ、積極的な疾患管理であれ、目的とする臨床応用に特化したワクチン成果の的を絞ったレビューが可能となります。

技術革新が差別化を促進する製剤領域では、さらなる細分化が見られます。市場は、細胞ベースワクチン、核酸ベースワクチン、ペプチド/タンパク質ベースワクチン、合成ワクチン、ウイルスベクタベースワクチンに分類されます。細胞ベースのワクチン製剤を深く掘り下げると、樹状細胞ワクチンや腫瘍細胞ワクチンなど、効果的な免疫反応を刺激する上で重要な追加層が明らかになります。DNAワクチンとRNAワクチンに細分化される核酸ベースの製剤の並行的な進歩は、その迅速な開発サイクルとカスタマイズ可能なコンストラクトにより、幅広い関心を集めています。

投与経路を考えると、ワクチンは一般的に筋肉内投与か静脈内投与のいずれかの経路で投与されます。それぞれの投与経路は、バイオアベイラビリティと患者の快適性に関連した明確な利点を提供するため、臨床場面での徹底的な分析が必要です。このセグメンテーションは、臨床検査だけでなく、第Ⅰ相、第Ⅱ相、第Ⅲ相といった明確な検査フェーズを含む開発フェーズに基づいてさらに細分化されます。これらのフェーズは、各ワクチン候補の成熟度を示すだけでなく、将来の市場参入と拡大の可能性を測る上で極めて重要なチェックポイントとなります。

さらに、適応症別セグメンテーションは、様々ながん種における洞察に満ちた差別化を記載しています。乳がん、大腸がん、肺がん、黒色腫、前立腺がんなどの疾患を対象としたワクチンの普及は、研究により一貫して強調されています。各適応症は独自の課題と機会を提示しており、その結果、対象とする研究、資金調達、市場浸透戦略に影響を与えます。

最後のセグメンテーションでは、エンドユーザーに焦点を当て、さまざまな医療環境に基づいて市場を分類します。使用事例は、がん研究機関、病院クリニック、がん専門治療センターなど多岐にわたります。この多様なセグメンテーションにより、市場全体の理解が深まり、インフラやリソースの有無が新規がんワクチンの採用や成功にどのように影響するかが明らかになります。

これらの市場セグメンテーションの知見を総合すると、市場を詳細に把握することができ、マーケティング戦略、規制当局との調整、地域的・世界の臨床ニーズに合わせた技術革新の促進における精度の重要性が浮き彫りになります。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でがんの罹患率が増加
    • がんワクチンの導入を加速させる政府の支援施策と資金援助プログラム
  • 抑制要因
    • がんワクチン技術の開発コストの高さ
  • 機会
    • がんワクチンの新興国の開発と有効性を高める新興技術とイノベーション
    • バイオ医薬品企業間の協力と提携がワクチン開発を加速
  • 課題
    • がんワクチンの調査と流通を制限する規制とコンプライアンスの問題
• 市場セグメンテーション分析
  • 製品タイプ：健康な人のがんの発症を防ぐ予防がんワクチンの新興国の需要の高まり
  • エンドユーザー：がん治療センターにおける個別化医療への関心の高まり
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 がんワクチン市場：製品タイプ別

• イントロダクション
• 予防用がんワクチン
• 治療用がんワクチン

第7章 がんワクチン市場：製剤別

• イントロダクション
• 細胞ベースのワクチン
  • 樹状細胞ワクチン
  • 腫瘍細胞ワクチン
• 核酸ベースのワクチン
  • DNAワクチン
  • RNAワクチン
• ペプチド/タンパク質ベースのワクチン
• 合成ワクチン
• ウイルスベクタベースのワクチン

第8章 がんワクチン市場：投与経路別

• イントロダクション
• 筋肉内
• 静脈内

第9章 がんワクチン市場：開発フェーズ別

• イントロダクション
• 臨床検査
• フェーズI
• フェーズII
• フェーズIII

第10章 がんワクチン市場：適応症別

• イントロダクション
• 乳がん
• 大腸がん
• 肺がん
• 黒色腫
• 前立腺がん

第11章 がんワクチン市場：エンドユーザー別

• イントロダクション
• がん研究機関
• 病院とクリニック
• 専門がん治療センター

第12章 南北アメリカのがんワクチン市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋のがんワクチン市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカのがんワクチン市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析、2024年
• FPNVポジショニングマトリックス、2024年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Advaxis Inc.
• Amgen Inc.
• AstraZeneca PLC
• Bayer AG
• BioNTech SE
• Bristol Myers Squibb Company
• Celldex Therapeutics
• Dynavax Technologies
• Eli Lilly and Company
• GSK PLC
• Heat Biologics, Inc.
• Helsinn Healthcare SA
• Johnson & Johnson
• Merck & Co., Inc.
• Moderna, Inc.
• Pfizer Inc.
• Sanofi SA
• Sanpower Group Co., Ltd.
• Serum Institute of India Pvt. Ltd.
• Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. CANCER VACCINES MARKET MULTI-CURRENCY
• FIGURE 2. CANCER VACCINES MARKET MULTI-LANGUAGE
• FIGURE 3. CANCER VACCINES MARKET RESEARCH PROCESS
• FIGURE 4. CANCER VACCINES MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL CANCER VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL CANCER VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL CANCER VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL CANCER VACCINES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL CANCER VACCINES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. AMERICAS CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. AMERICAS CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. UNITED STATES CANCER VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 23. UNITED STATES CANCER VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. CANCER VACCINES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 29. CANCER VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CANCER VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CANCER VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CANCER VACCINES MARKET DYNAMICS
• TABLE 7. GLOBAL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CANCER VACCINES MARKET SIZE, BY PREVENTIVE CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CANCER VACCINES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CANCER VACCINES MARKET SIZE, BY TUMOR CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CANCER VACCINES MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CANCER VACCINES MARKET SIZE, BY RNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CANCER VACCINES MARKET SIZE, BY PEPTIDE/PROTEIN-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CANCER VACCINES MARKET SIZE, BY SYNTHETIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CANCER VACCINES MARKET SIZE, BY VIRAL VECTOR-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CANCER VACCINES MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CANCER VACCINES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL CANCER VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL CANCER VACCINES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL CANCER VACCINES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL CANCER VACCINES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL CANCER VACCINES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL CANCER VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL CANCER VACCINES MARKET SIZE, BY SPECIALTY CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. CANADA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 66. CANADA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 67. CANADA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 68. CANADA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 69. CANADA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 70. CANADA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 71. CANADA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. CANADA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. MEXICO CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 77. MEXICO CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. UNITED STATES CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES CANCER VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 90. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 92. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 94. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 99. AUSTRALIA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. AUSTRALIA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 101. AUSTRALIA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 102. AUSTRALIA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 103. AUSTRALIA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 104. AUSTRALIA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 105. AUSTRALIA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. AUSTRALIA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. CHINA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 108. CHINA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 109. CHINA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 110. CHINA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 111. CHINA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 112. CHINA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 113. CHINA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 114. CHINA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. INDIA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 116. INDIA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 117. INDIA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 118. INDIA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 119. INDIA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 120. INDIA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 121. INDIA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 122. INDIA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. INDONESIA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 124. INDONESIA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 125. INDONESIA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 126. INDONESIA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 127. INDONESIA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 128. INDONESIA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 129. INDONESIA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. INDONESIA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. JAPAN CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 132. JAPAN CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 133. JAPAN CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 134. JAPAN CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 135. JAPAN CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 136. JAPAN CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 137. JAPAN CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 138. JAPAN CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. MALAYSIA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 140. MALAYSIA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 141. MALAYSIA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 142. MALAYSIA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 143. MALAYSIA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 144. MALAYSIA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 145. MALAYSIA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. MALAYSIA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. PHILIPPINES CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 148. PHILIPPINES CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 149. PHILIPPINES CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 150. PHILIPPINES CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 151. PHILIPPINES CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 152. PHILIPPINES CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 153. PHILIPPINES CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 154. PHILIPPINES CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 155. SINGAPORE CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 156. SINGAPORE CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 157. SINGAPORE CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 158. SINGAPORE CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 159. SINGAPORE CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 160. SINGAPORE CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 161. SINGAPORE CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 162. SINGAPORE CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. TAIWAN CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 172. TAIWAN CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 173. TAIWAN CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 174. TAIWAN CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 175. TAIWAN CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 176. TAIWAN CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 177. TAIWAN CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 178. TAIWAN CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 179. THAILAND CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 180. THAILAND CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 181. THAILAND CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 182. THAILAND CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 183. THAILAND CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 184. THAILAND CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 185. THAILAND CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 186. THAILAND CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 187. VIETNAM CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 188. VIETNAM CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 189. VIETNAM CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 190. VIETNAM CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 191. VIETNAM CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 192. VIETNAM CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 193. VIETNAM CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 194. VIETNAM CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 204. DENMARK CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 205. DENMARK CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 206. DENMARK CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 207. DENMARK CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 208. DENMARK CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 209. DENMARK CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 210. DENMARK CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 211. DENMARK CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 212. EGYPT CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 213. EGYPT CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 214. EGYPT CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 215. EGYPT CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 216. EGYPT CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 217. EGYPT CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 218. EGYPT CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 219. EGYPT CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 220. FINLAND CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 221. FINLAND CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 222. FINLAND CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 223. FINLAND CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 224. FINLAND CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 225. FINLAND CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 226. FINLAND CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 227. FINLAND CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 228. FRANCE CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 229. FRANCE CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 230. FRANCE CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 231. FRANCE CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 232. FRANCE CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 233. FRANCE CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 234. FRANCE CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 235. FRANCE CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 236. GERMANY CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 237. GERMANY CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 238. GERMANY CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 239. GERMANY CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 240. GERMANY CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 241. GERMANY CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 242. GERMANY CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 243. GERMANY CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 244. ISRAEL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 245. ISRAEL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 246. ISRAEL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 247. ISRAEL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 248. ISRAEL CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 249. ISRAEL CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 250. ISRAEL CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 251. ISRAEL CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 252. ITALY CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 253. ITALY CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 254. ITALY CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 255. ITALY CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 256. ITALY CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 257. ITALY CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 258. ITALY CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 259. ITALY CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 260. NETHERLANDS CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 261. NETHERLANDS CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 262. NETHERLANDS CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 263. NETHERLANDS CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 264. NETHERLANDS CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 265. NETHERLANDS CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 266. NETHERLANDS CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 267. NETHERLANDS CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 268. NIGERIA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 269. NIGERIA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 270. NIGERIA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 271. NIGERIA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 272. NIGERIA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 273. NIGERIA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 274. NIGERIA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 275. NIGERIA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 276. NORWAY CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 277. NORWAY CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 278. NORWAY CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 279. NORWAY CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 280. NORWAY CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 281. NORWAY CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 282. NORWAY CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 283. NORWAY CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 284. POLAND CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 285. POLAND CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 286. POLAND CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 287. POLAND CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 288. POLAND CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 289. POLAND CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 290. POLAND CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 291. POLAND CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 292. QATAR CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 293. QATAR CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 294. QATAR CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 295. QATAR CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 296. QATAR CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 297. QATAR CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 298. QATAR CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 299. QATAR CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 300. RUSSIA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 301. RUSSIA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 302. RUSSIA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 303. RUSSIA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 304. RUSSIA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 305. RUSSIA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 306. RUSSIA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 307. RUSSIA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 308. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 309. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 310. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 311. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 312. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 313. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 314. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 315. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 316. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 317. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 318. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 319. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 320. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 321. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 322. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 323. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 324. SPAIN CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 325. SPAIN CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 326. SPAIN CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 327. SPAIN CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 328. SPAIN CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 329. SPAIN CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 330. SPAIN CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 331. SPAIN CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 332. SWEDEN CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 333. SWEDEN CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 334. SWEDEN CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 335. SWEDEN CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 336. SWEDEN CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 337. SWEDEN CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 338. SWEDEN CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 339. SWEDEN CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 340. SWITZERLAND CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 341. SWITZERLAND CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 342. SWITZERLAND CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 343. SWITZERLAND CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 344. SWITZERLAND CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2030 (USD MILLION)
• TABLE 345. SWITZERLAND CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
• TABLE 346. SWITZERLAND CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 347. SWITZERLAND CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 348. TURKEY CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 349. TURKEY CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2030

The Cancer Vaccines Market was valued at USD 7.11 billion in 2024 and is projected to grow to USD 7.78 billion in 2025, with a CAGR of 9.60%, reaching USD 12.33 billion by 2030.

The cancer vaccines market has emerged as one of the most promising segments in advanced therapeutic solutions, reflecting both a deep scientific evolution and a mounting urgency to address cancer's global burden. Over the past few decades, significant strides in immunology and biotechnology have transformed our understanding of the body's ability to combat malignancies. This progress is anchored in discoveries that harness the immune system to identify and target cancer cells and has paved the way for both preventive and therapeutic modalities.

Recent developments have not only expanded the scientific basis behind these vaccines but have also led to novel clinical applications and transformative regulatory pathways. The convergence of breakthrough research, patient-centric therapies, and strategic collaborations has accelerated market dynamics - all while reshaping the competitive landscape on a global scale. As we delve into each facet of this evolving market, it is essential to recognize the multidisciplinary factors that underpin its rapid emergence as a key pillar in modern oncology.

This summary provides a comprehensive overview, articulating current trends, segmentation insights, global regional influences, key players' advancements, and strategic recommendations to help decision-makers and industry experts navigate an increasingly complex market. Through this lens, stakeholders can better appreciate the innovation cycles, regulatory climates, and dynamic interplay between technological advancements and cancer treatment paradigms.

Transformative Shifts in the Dynamic Cancer Vaccines Sector

In recent years, the landscape of cancer vaccines has undergone seismic shifts driven by a combination of scientific breakthroughs, improved manufacturing technologies, and enhanced regulatory support. This evolution is being championed by innovative therapies that, while rooted in traditional immunological principles, have vastly expanded in both scope and sophistication. Several transformative trends have emerged:

First, there is an increasing emphasis on personalized medicine, where tailored vaccines are developed based on individual tumor antigens. This strategy not only heightens the precision of treatment but also minimizes off-target effects, leading to improved patient outcomes. The integration of state-of-the-art genomic and proteomic profiling has been instrumental in identifying novel targets, thereby refining vaccine design.

In parallel, the field is witnessing robust advancements in formulation technologies. Cutting-edge platforms such as nucleic acid-based vaccines have opened new avenues for rapid design and scalable production, positioning them as frontrunners in the race to bring novel therapeutic options to market. Enhanced methods, including cell-based and synthetic vaccine formulations, are also being refined to improve their safety profiles, efficacy, and delivery mechanisms.

Another profound shift is seen in the strategic collaboration between pharmaceutical companies, academic institutions, and regulatory bodies, which has significantly diminished traditional roadblocks in clinical trials and accelerated the path to commercialization. Moreover, the integration of artificial intelligence and big data analytics in vaccine research is not only streamlining R&D processes but also unveiling deeper insights into disease mechanisms.

Finally, shifting patient expectations and increased public investment in cancer research have provided impetus for emerging players and established companies alike to innovate continuously. These drivers have collectively contributed to a vibrant market landscape, prompting key industry stakeholders to reassess and realign their strategic frameworks in response to these disruptive changes.

Comprehensive Segmentation Insights for Detailed Market Analysis

A nuanced understanding of market segmentation is essential to appreciate the diverse layers that define the cancer vaccines landscape. The market is primarily segmented based on product type, with detailed analysis across preventive cancer vaccines and therapeutic cancer vaccines. This division allows for a targeted review of vaccine outcomes specific to the intended clinical application, whether for prophylactic intervention or active disease management.

Further segmentation is observed in formulation domains where technological innovations drive differentiation. The market is dissected across cell-based vaccines, nucleic acid-based vaccines, peptide/protein-based vaccines, synthetic vaccines, and viral vector-based vaccines. A deep dive into cell-based vaccine formulations reveals additional layers, including dendritic cell vaccines and tumor cell vaccines, which are critical in stimulating an effective immune response. Parallel advancements in nucleic acid-based formulations, subdivided into DNA vaccines and RNA vaccines, have fostered broad interest due to their rapid development cycles and customizable constructs.

When considering the administration pathways, vaccines are typically delivered either via intramuscular or intravenous routes. Each pathway offers distinct advantages pertaining to bioavailability and patient comfort, warranting thorough analysis in clinical contexts. This segmentation is further refined based on the development phase, which includes clinical trials as well as distinct trial phases such as Phase I, Phase II, and Phase III. These phases not only indicate the maturity of each vaccine candidate but also serve as pivotal checkpoints in gauging future market entry and expansion potential.

Additionally, segmentation by indication provides insightful differentiation across various cancer forms. Studies consistently highlight the prevalence of vaccines targeted at diseases such as breast cancer, colorectal cancer, lung cancer, melanoma, and prostate cancer. Each indication presents unique challenges and opportunities, thereby influencing targeted research, funding, and market penetration strategies.

The final segmentation dimension focuses on the end-user, categorizing the market based on different healthcare settings. The use cases span cancer research institutes, hospitals and clinics, and specialty cancer treatment centers. This diversified segmentation enriches the overall market understanding, revealing how infrastructure and resource availability can markedly affect the adoption and success of novel cancer vaccines.

Collectively, these segmentation insights offer a granular view of the market and underscore the importance of precision in marketing strategies, regulatory alignment, and fostering innovation tailored to meet localized as well as global clinical needs.

Based on Product Type, market is studied across Preventive Cancer Vaccines and Therapeutic Cancer Vaccines.

Based on Formulations, market is studied across Cell-Based Vaccines, Nucleic Acid-Based Vaccines, Peptide/Protein-Based Vaccines, Synthetic Vaccines, and Viral Vector-Based Vaccines. The Cell-Based Vaccines is further studied across Dendritic Cell Vaccines and Tumor Cell Vaccines. The Nucleic Acid-Based Vaccines is further studied across DNA Vaccines and RNA Vaccines.

Based on Administration Pathway, market is studied across Intramuscular and Intravenous.

Based on Development Phase, market is studied across Clinical Trials, Phase I, Phase II, and Phase III.

Based on Indication, market is studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer.

Based on End-User, market is studied across Cancer Research Institutes, Hospitals & Clinics, and Specialty Cancer Treatment Centers.

Regional Market Insights Shaping Global Trends

On a global scale, the cancer vaccines market is experiencing varied trajectories across regions, each contributing distinct insights into the overall growth dynamics. In the Americas, a surge in healthcare innovation combined with well-established research facilities and significant investment in immunotherapy has led to rapid market adoption and accelerated clinical development pathways. This region continues to serve as a benchmark for regulatory excellence and clinical efficacy, driving trends that reverberate throughout the world.

Moving to Europe, Middle East and Africa, the market is marked by a unique blend of advanced scientific research and emerging markets that are gradually ramping up investment in biotechnology. The region's focus on collaborative research, cross-border clinical trials, and policy reforms aiming to expedite vaccine approvals have augmented its role as a pivotal player. Such advancements are complemented by strong public-private partnerships that encourage both early-stage development and fast-tracking of therapeutic candidates.

In the Asia-Pacific region, the narrative is defined by rapid economic growth, government-led initiatives in healthcare, and an increasingly sophisticated understanding of cancer pathophysiology. This region has become a fertile ground for innovative formulations and technology-driven solutions, largely fueled by an expanding clinical research infrastructure and a growing patient base. The market here is characterized by dynamic shifts in clinical adoption practices and a marked preference for personalized treatments backed by robust local data.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Insights Driving Innovation and Competition

The competitive landscape of the cancer vaccines market is characterized by the strategic manoeuvres of several key players who are at the forefront of research and development. Industry leaders such as Advaxis Inc. and Amgen Inc. continue to influence the trajectory of vaccine innovation with an unwavering focus on harnessing the power of the immune system. AstraZeneca PLC and Bayer AG have made significant contributions through cutting-edge research collaborations and robust portfolio expansions, aimed at improving clinical outcomes and reducing the treatment burden.

Other prominent entities such as BioNTech SE and Bristol Myers Squibb Company are leveraging next-generation platforms to push the boundaries of vaccine efficacy while Celldex Therapeutics and Dynavax Technologies are pioneering promising candidates that bring new hope to intractable cancer types. Eli Lilly and Company and GSK PLC have maintained their steadfast commitment to advancing clinical programs with a focus on precision administration and safety, further emphasizing their role in the transformative evolution of cancer treatment.

Additional influential companies include Heat Biologics, Inc. and Helsinn Healthcare SA, which have secured a prominent stature by virtue of their innovative approaches and strategic collaborations. Industry behemoths like Johnson & Johnson and Merck & Co., Inc. provide not only financial muscle but also critical clinical insights which catalyze innovations across the board. Moderna, Inc. and Pfizer Inc. have been instrumental in pioneering nucleic acid-based vaccine technologies that promise rapid and tailored therapeutic interventions.

Sanofi SA, Sanpower Group Co., Ltd., Serum Institute of India Pvt. Ltd., and Sun Pharmaceutical Industries Ltd. round off this competitive outlook by reinforcing the market's global footprint. Their continued investment in research, manufacturing, and clinical trials adds value to the overall ecosystem and underscores the collective effort to overcome the multifaceted challenges posed by cancer.

The report delves into recent significant developments in the Cancer Vaccines Market, highlighting leading vendors and their innovative profiles. These include Advaxis Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, BioNTech SE, Bristol Myers Squibb Company, Celldex Therapeutics, Dynavax Technologies, Eli Lilly and Company, GSK PLC, Heat Biologics, Inc., Helsinn Healthcare SA, Johnson & Johnson, Merck & Co., Inc., Moderna, Inc., Pfizer Inc., Sanofi SA, Sanpower Group Co., Ltd., Serum Institute of India Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.. Actionable Recommendations for Strategic Market Positioning

To successfully navigate the complex and rapidly evolving cancer vaccines market, industry leaders must adopt a multi-dimensional strategy that emphasizes innovation, collaboration, and patient-centric solutions. Firstly, it is imperative to invest in research and development, particularly in the emerging areas of nucleic acid-based and cell-based vaccine technologies. Companies should forge strategic alliances with academic centers and public research institutions to accelerate the transition from bench to bedside.

Enhancing regulatory compliance and actively engaging with governing bodies will further streamline the pathway to market approval. By establishing early dialogues with regulatory agencies, firms can gain critical insights into evolving requirements and harmonize clinical trial designs with global standards, ensuring a smoother approval process across multiple regions.

Embracing digital transformation is another cornerstone of future success. Advanced data analytics and artificial intelligence can not only optimize clinical trial designs but also enable personalized treatment regimens that significantly improve outcome metrics. As the market shifts toward more precise treatment protocols, leveraging digital tools will be key to unlocking hidden insights and identifying untapped opportunities.

Market segmentation plays a central role in developing targeted commercialization strategies. With a clear understanding of differentiated needs across product types, formulations, administration routes, and disease indications, companies can more effectively tailor their marketing strategies. Decision-makers should consider localized market dynamics, catering efforts according to region-specific regulatory, economic, and cultural factors.

Another actionable recommendation is to diversify end-user outreach. By broadening engagement across cancer research institutes, hospitals and clinics, and specialized cancer treatment centers, companies can foster a more inclusive market ecosystem. This approach not only facilitates rapid feedback on product performance but also builds lasting relationships based on trust and proven clinical efficacy.

Lastly, companies should maintain an agile operational model that allows for quick adaptation in response to emerging scientific evidence and market shifts. By cultivating a culture of innovation and remaining receptive to industry disruptions, organizations can secure a competitive edge and sustainably drive growth in an ever-evolving market.

Conclusion and Forward-Looking Perspectives

In summary, the cancer vaccines market stands at the nexus of innovation and clinical need, offering unparalleled opportunities for transformative healthcare breakthroughs. The evolving market dynamics - characterized by robust scientific advances, regulatory realignments, and increasing collaboration across disciplines - have created an environment ripe for disruption and sustainable growth. Through a comprehensive segmentation that dissects product types, formulation technologies, administration pathways, development phases, disease indications, and end-user profiles, a clearer picture of both challenges and opportunities emerges.

Industry-leading companies continue to push the envelope with innovative technologies that promise faster, more effective, and safer solutions for cancer patients worldwide. These efforts, combined with regional insights that underscore the varying degrees of market maturity across the Americas, Europe, Middle East and Africa, and Asia-Pacific, highlight a future where personalized medicine and precision therapies take center stage. As these trends converge, strategic adaptability and a commitment to long-term research and partnerships will be pivotal in driving the next phase of market expansion.

The integration of new technologies such as artificial intelligence, big data analytics, and advanced manufacturing processes only further underscores the imperative for organizations to remain agile and responsive to change. Such adaptability not only enhances the ability to meet diverse clinical needs but also demonstrates a forward-looking approach that is essential for sustainable success in the competitive healthcare landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of cancer cases worldwide
    • 5.1.1.2. Supportive governmental policies and funded programs accelerating cancer vaccine deployment
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of development of cancer vaccine technology
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging technologies and innovations enhancing the development and effectiveness of cancer vaccines
    • 5.1.3.2. Collaborations and partnerships among biopharmaceutical companies accelerating vaccine development
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory and compliance issues restricting cancer vaccine research and distribution
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type: Rising demand for preventive cancer vaccines to stop cancer from developing in healthy individuals
  • 5.2.2. End-User: Growing preference of cancer treatment centers for personalized medicines
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cancer Vaccines Market, by Product Type

• 6.1. Introduction
• 6.2. Preventive Cancer Vaccines
• 6.3. Therapeutic Cancer Vaccines

7. Cancer Vaccines Market, by Formulations

• 7.1. Introduction
• 7.2. Cell-Based Vaccines
  • 7.2.1. Dendritic Cell Vaccines
  • 7.2.2. Tumor Cell Vaccines
• 7.3. Nucleic Acid-Based Vaccines
  • 7.3.1. DNA Vaccines
  • 7.3.2. RNA Vaccines
• 7.4. Peptide/Protein-Based Vaccines
• 7.5. Synthetic Vaccines
• 7.6. Viral Vector-Based Vaccines

8. Cancer Vaccines Market, by Administration Pathway

• 8.1. Introduction
• 8.2. Intramuscular
• 8.3. Intravenous

9. Cancer Vaccines Market, by Development Phase

• 9.1. Introduction
• 9.2. Clinical Trials
• 9.3. Phase I
• 9.4. Phase II
• 9.5. Phase III

10. Cancer Vaccines Market, by Indication

• 10.1. Introduction
• 10.2. Breast Cancer
• 10.3. Colorectal Cancer
• 10.4. Lung Cancer
• 10.5. Melanoma
• 10.6. Prostate Cancer

11. Cancer Vaccines Market, by End-User

• 11.1. Introduction
• 11.2. Cancer Research Institutes
• 11.3. Hospitals & Clinics
• 11.4. Specialty Cancer Treatment Centers

12. Americas Cancer Vaccines Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Cancer Vaccines Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Cancer Vaccines Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Scenario Analysis
  • 15.3.1. University of Oxford and Univercells team up to transform RNA cancer vaccine development with cutting-edge collaboration
  • 15.3.2. Moderna's mRNA-4359 cancer vaccine Shows early promise in trials
  • 15.3.3. Infinitopes raises EUR 12.8m to pioneer precision immunomics in cancer vaccines targeting multiple cancers
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Advaxis Inc.
• 2. Amgen Inc.
• 3. AstraZeneca PLC
• 4. Bayer AG
• 5. BioNTech SE
• 6. Bristol Myers Squibb Company
• 7. Celldex Therapeutics
• 8. Dynavax Technologies
• 9. Eli Lilly and Company
• 10. GSK PLC
• 11. Heat Biologics, Inc.
• 12. Helsinn Healthcare SA
• 13. Johnson & Johnson
• 14. Merck & Co., Inc.
• 15. Moderna, Inc.
• 16. Pfizer Inc.
• 17. Sanofi SA
• 18. Sanpower Group Co., Ltd.
• 19. Serum Institute of India Pvt. Ltd.
• 20. Sun Pharmaceutical Industries Ltd.